Cancer investigation · 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Клиническое исследование II фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mey Ulrich J M, Orlopp Katjana S, Flieger Dimitri, Strehl John W, Ho Anthony D, Hensel Manfred, Bopp Cordula, Gorschlüter Marcus, Wilhelm Martin, Birkmann Josef, Kaiser Ulrich, Neubauer Andreas, Florschütz Axel, Rabe Christian, Hahn Corinna, Glasmacher Axel G, Schmidt-Wolf Ingo G H
Аннотация
We designed a multicenter Phase II trial to prospectively evaluate the efficacy and safety of the combination of rituximab with the DHAP regimen (dexamethasone, high-dose cytarabine, cisplatin) in patients who relapsed after or were resistant to a CHOP-like regimen. A total of 53 patients with relapsed or resistant aggressive B-cell NHL were analyzed. The overall response rate was 62.3 percent. With a median follow-up of 24.9 months, median overall and progression-free survivals were 8.5 and 6.7 months, respectively. Immunochemotherapy with rituximab and DHAP proved to be feasible and effective in this patient population.
Предметные рубрики MeSH
AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCisplatinCytarabineDexamethasoneDisease-Free SurvivalDose-Response Relationship, DrugDrug Resistance, NeoplasmFemaleHumansLymphoma, B-CellLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRituximabSalvage TherapySurvival RateTreatment Outcome